Akttyva Therapeutics
Akttyva Therapeutics speeds discovery of targeted treatments for diseases caused by vascular leakage. The company uses an AI-assisted drug-discovery platform, AIDE-360, that combines machine learning, neural networks, cheminformatics, physics-based approaches, and unique compound libraries with experimental validation. It operates as a drug-discovery platform company working with pharmaceutical and biotechnology partners and maintains wet labs in Watertown, Massachusetts. Akttyva has received National Science Foundation support for its computational-experimental platform.
Akttyva Therapeutics
Akttyva Therapeutics speeds discovery of targeted treatments for diseases caused by vascular leakage. The company uses an AI-assisted drug-discovery platform, AIDE-360, that combines machine learning, neural networks, cheminformatics, physics-based approaches, and unique compound libraries with experimental validation. It operates as a drug-discovery platform company working with pharmaceutical and biotechnology partners and maintains wet labs in Watertown, Massachusetts. Akttyva has received National Science Foundation support for its computational-experimental platform.
TL;DR
Sector: Biotechnology — AI-assisted drug discovery
Headquarters: Massachusetts (Mansfield and Watertown)
Founders: Katya Tsaioun, Ph.D.; Usamah Kayyali, Ph.D.
Platform: AIDE-360 AI-powered drug-discovery platform
Notable funding: NSF grants and MassChallenge non-equity support
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Cell barrier dysfunction and vascular leak disorders
Founded
2020
Industry
Biotechnology
Funding Track Record
MassChallenge non-equity support recorded June 2021.
260000 USD
NSF grant recorded Nov 30, 2021 (Crunchbase/Dealroom entries).
Investor Signal
“Non-dilutive grant and program support (National Science Foundation, MassChallenge)”